|2010||Professor, Chemical Engineering Department, Imperial College London|
|2007-10||Reader, Chemical Engineering Department, Imperial College London|
Governor''s Lecturer, Chemical Engineering Department, Imperial College London
PhD in Chemical Engineering, University of Rochester, U.S.A., Thesis title: “Engineering a Human Ex Vivo Bone Marrow Mimicry”
MSc Chemical Engineering, University of Rochester, U.S.A.
BSc (Hons) Biochemistry, UWO, Canada
My research interests lie in the areas of stem cell bioprocessing, tissue engineering and mammalian cell bioprocessing.
- Stem Cell Bioprocessing: The fundamental bottleneck of any bioprocess is the lack of real-time, on-line, in-situ, quantitative information with respect to cellular behaviour in culture. as a result, control, optimisation, and scale-up of bioprocesses are essentially manual (empirical), which results in sub-optimal productivity (i.e., inadequate cell expansion) and product quality (i.e., inconsistent cell phenotypes). To harness the immense potential of stem cells (SCS) in terms of their plasticity and expansion capabilities, the physiological activity in relation to the culture parameters (local) such as ph, dissolved oxygen, nutrients/metabolite concentrations and growth factor concentrations needs to be recorded quantitatively with the needed level of accuracy and subsequently evaluated in a biologically meaningful manner. My laboratory (BSEL), in collaboration with Dr. Drakakis (Bioengineering), Profs. Cass and Toumazou (IBE), Prof. Dame J. Polak (TERM), and Dr. Panoskaltsis (Haematology) is seeking to develop such a novel monitoring modality that allows the systematic development of clinically relevant culture systems and methodologies, which control and regulate stem cell self-renewal, expansion, differentiation, and death. Ultimately, such a breakthrough will lead to the engineering of reproducible, well-characterised, regenerated “designer” tissues and organs that meet the strict regulatory criteria for clinical applications. the engineering challenge involved in the fabrication of the proposed modality can only be met by the cross-fertilisation and amalgamation of expertise of cell biologists, engineers, scientists, and clinicians. Furthermore, my laboratory is currently working, in collaboration with Prof. Polak and Dr. Bishop(TERM), in developing intergated processes and culture systems for the expansion and differentiation of embryonic stem cells.
- Tissue Engineering: Tissue engineering is an interdisciplinary field at the intersection of engineering, and biology and medicine. it requires the considerable input from biological scientists, who provide the insight to the various developmental control mechanisms of the cell and are able to manipulate the cell at a genetic level, and the contribution of material scientists who develop the structural scaffolds. My laboratory (BSEL) is seeking to provide integrated solutions to tissue engineering problems working close with material scientists (Dr. Bismarck) and modellers (Drs. Xu and Stepanek) to develop suitable scaffolds and culture systems for a variety of applications ranging from bone marrow, bone, cartilage, pneumocytes (Dr. Bishop), and cardiomyocytes (Prof. Polak), as well as developing ex vivo models for disease states, such as leukaemia (Dr. Panoskaltsis).
- Mammalian Cell Bioprocessing: Animal cell technology is an area of rapid expansion and one that produces a wide range of high-value products, including vaccines, recombinant proteins, drugs for cardiovascular, respiratory and immune diseases, and monoclonal antibodies. commercial synthesis of monoclonal antibodies (mAb) represents one of the most important products in the biopharmaceutical industry because of their diagnostic and clinical applications. However, the production of industrial scale quantities of mAb is an expensive and challenging task. There are a number of complications that make it a difficult process to ensure that the culture is growing under optimal conditions at all times. Furthermore, the process control and optimisation in the hybridoma culture industry lags far behind the developments in other process industries; as a result, the current industrial control of hybridoma cell culture is still fundamentally manual. Complications arising in these systems include the requirement to grow cultures in complex media, the lack of on-line measurements for many of the key substrates, metabolites, and products, the limited and noisy nature of much of the available experimental data and the extremely complex underlying reaction system. Models of animal cell culture systems have a wide range of potential applications, such as analysis and prediction of experimental results, optimisation of culture conditions for prolonged viability, and perhaps most importantly, the investigation of fundamental metabolic processes and their subsequent elucidation. Our research programme sets out to integrate modelling, experiment design and validation, and control and optimisation into a single framework that would lead to increased productivity, regulated product quality, and reduced costs for mammalian cell culture systems. The integration of these three research tools represents a unique, novel, and interdisciplinary approach to addressing the complicated research and industrial problem of model-based control and optimisation of mammalian cell culture processes. This work is in collaboration with Prof. Stratos Pistikopoulos.
et al., 2011, Long-term cytokine-free expansion of cord blood mononuclear cells in three-dimensional scaffolds, Biomaterials, Vol:32, ISSN:0142-9612, Pages:9263-9270
et al., 2011, Linking genes to microbial growth kinetics-An integrated biochemical systems engineering approach, Metabolic Engineering, Vol:13, ISSN:1096-7176, Pages:401-413
et al., 2009, Global Sensitivity Analysis Challenges in Biological Systems Modeling, Industrial & Engineering Chemistry Research, Vol:48, ISSN:0888-5885, Pages:7168-7180
et al., 2009, The use of murine embryonic stem cells, alginate encapsulation, and rotary microgravity bioreactor in bone tissue engineering, Biomaterials, Vol:30, ISSN:0142-9612, Pages:499-507